GSE52133 LIN-41 knockdown 0 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE52133_LIN-41 knockdown_0_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE52133_LIN-41 knockdown_0_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE52133_LIN-41 knockdown_0_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE52133_LIN-41 knockdown_0_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 5

Gene

ABCF2-H2BK1 readthrough

Gene

FEZF1 antisense RNA 1

Gene

NUTM2A antisense RNA 1

Gene

sphingomyelin phosphodiesterase 4B, pseudogene

Gene

lipoprotein(a) like 2 (pseudogene)

Gene

FAM222A antisense RNA 1

Gene

ATP binding cassette subfamily A member 11, pseudogene

Gene

JAKMIP2 antisense RNA 1

Gene

long intergenic non-protein coding RNA 499

  • Gene

    small nucleolar RNA host gene 5


  • Gene

    ABCF2-H2BK1 readthrough


  • Gene

    FEZF1 antisense RNA 1


  • Gene

    NUTM2A antisense RNA 1


  • Gene

    sphingomyelin phosphodiesterase 4B, pseudogene


  • Gene

    lipoprotein(a) like 2 (pseudogene)


  • Gene

    FAM222A antisense RNA 1


  • Gene

    ATP binding cassette subfamily A member 11, pseudogene


  • Gene

    JAKMIP2 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 499

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.